Interesting update on Louisa Nicola – Neurophysiologist Warns About the Hidden Dangers of Black-Market Peptides | SRS #300. Curious how the grades will trend next quarter.
Interesting update on Louisa Nicola – Neurophysiologist Warns About the Hidden Dangers of Black-Market Peptides | SRS #300. Curious how the grades will trend next quarter.
Interesting update on Louisa Nicola – Neurophysiologist Warns About the Hidden Dangers of Black-Market Peptides | SRS #300. Curious how the grades will trend next quarter.
Interesting update on Louisa Nicola – Neurophysiologist Warns About the Hidden Dangers of Black-Market Peptides | SRS #300. Curious how the grades will trend next quarter.
Interesting update on Louisa Nicola – Neurophysiologist Warns About the Hidden Dangers of Black-Market Peptides | SRS #300. Curious how the grades will trend next quarter.
46 Comments
I like the balance sheet here—less leverage than peers.
If AISC keeps dropping, this becomes investable for me.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
The cost guidance is better than expected. If they deliver, the stock could rerate.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Nice to see insider buying—usually a good signal in this space.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Interesting update on Louisa Nicola – Neurophysiologist Warns About the Hidden Dangers of Black-Market Peptides | SRS #300. Curious how the grades will trend next quarter.
Uranium names keep pushing higher—supply still tight into 2026.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Nice to see insider buying—usually a good signal in this space.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Exploration results look promising, but permitting will be the key risk.
Interesting update on Louisa Nicola – Neurophysiologist Warns About the Hidden Dangers of Black-Market Peptides | SRS #300. Curious how the grades will trend next quarter.
Interesting update on Louisa Nicola – Neurophysiologist Warns About the Hidden Dangers of Black-Market Peptides | SRS #300. Curious how the grades will trend next quarter.
Good point. Watching costs and grades closely.
Uranium names keep pushing higher—supply still tight into 2026.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
I like the balance sheet here—less leverage than peers.
Interesting update on Louisa Nicola – Neurophysiologist Warns About the Hidden Dangers of Black-Market Peptides | SRS #300. Curious how the grades will trend next quarter.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Nice to see insider buying—usually a good signal in this space.
Good point. Watching costs and grades closely.
I like the balance sheet here—less leverage than peers.
Interesting update on Louisa Nicola – Neurophysiologist Warns About the Hidden Dangers of Black-Market Peptides | SRS #300. Curious how the grades will trend next quarter.
I like the balance sheet here—less leverage than peers.
Silver leverage is strong here; beta cuts both ways though.
Uranium names keep pushing higher—supply still tight into 2026.
Uranium names keep pushing higher—supply still tight into 2026.
Good point. Watching costs and grades closely.
The cost guidance is better than expected. If they deliver, the stock could rerate.
Good point. Watching costs and grades closely.
Silver leverage is strong here; beta cuts both ways though.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
The cost guidance is better than expected. If they deliver, the stock could rerate.
Good point. Watching costs and grades closely.
Nice to see insider buying—usually a good signal in this space.
Good point. Watching costs and grades closely.